Please login to the form below

Not currently logged in
Email:
Password:

Targovax appoints Oystein Soug as CEO

CFO takes on top role as Gunnar Gårdemyr steps down

Targovax Oystein SougNorwegian immuno-oncology specialist Targovax has appointed Oystein Soug as its new chief executive officer following the resignation of Gunnar Gåardemyr.

Formerly chief financial officer, Soug joined Targovax in 2015 bringing over 20 years of financial management experience to the role.

He has previously served as chief financial officer for Algeta, a Norwegian oncology biotech that was bought by Bayer in 2014, and spent six years at Orkla, a Norwegian consumer goods company.

Jónas Einarsson, chairman of Targovax's board of directors, said: “We are delighted to announce the appointment of Oystein as the new chief executive officer of Targovax.

“He has played a key role as chief financial officer over the past year - successfully guiding us on the path to becoming a publicly-listed company, securing funding for further development of the company's ongoing and planned trials.

“We are confident in his ability to lead the company as we approach important milestones in 2017 and 2018 in our innovative clinical pipeline designed to help the patient's own immune system fight cancer.”

16th November 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics